External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study

What Was Tested

This randomized controlled trial paper looks at Goserelin.

In this report, the researchers present the 10-year results.

Who Took Part

PubMed tags the participants as men only.

For this open-label randomised trial, eligible patients were younger than 80 years and had newly diagnosed histologically proven T1-2 prostatic adenocarcinoma with WHO histological grade 3 or T3-4 prostatic adenocarcinoma of any histological grade, and a WHO performance status of 0-2.

Patients were randomly assigned (1:1) to receive radiotherapy alone or radiotherapy plus immediate androgen suppression.

How the Study Was Run

The design is described as randomized and open-label.

Random assignment meant chance, not the researchers, decided who got Goserelin and who got the comparison, which limits bias.

Everyone knew when Goserelin was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Treatment allocation was open label and used a minimisation algorithm with institution, clinical stage of the disease, results of pelvic-lymph-node dissection, and irradiation fields extension as minimisation factors.

The primary endpoint was clinical disease-free survival.

Analysis was by intention to treat.

The trial is registered at ClinicalTrials.gov, number NCT00849082.

What Was Measured

Topics PubMed links to this paper include Adenocarcinoma, Androgen Antagonists, Antineoplastic Combined Chemotherapy Protocols, Canada, Cardiovascular Diseases, Chemotherapy, Adjuvant and Cyproterone Acetate.

What This Means in Plain Language

The paper is a randomized and open-label study of Goserelin.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2010 (The Lancet. Oncology), a journal based in England.

More context: the Goserelin compound page.